Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Capping more than two years of stock-gyrating drama, Pfizer said it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another ...

Outside the US, Enbrel is marketed by Pfizer – but it also faces competition in Europe from another near-copy from Samsung Bioepis. The US is lagging behind Europe in the field of biosimilars ...

Enbrel revenues declined 16% to $169 million. New product Oxbryta generated sales of $17 million in the third quarter of 2024, down 80% year over year. In September, Pfizer announced that it is ...

The NHS saved nearly £99.4 million by using Infliximab, the biosimilar version of Jannssen’s Remicade and £60 million by switching from Amgen/Pfizer’s Enbrel to Etanercept. In addition two ...

In 2024, Enbrel generated $3.3 billion in revenue in the US. Sandoz received US FDA approval for Erelzi in 2016, the same year the company launched the medicine in Europe. Sandoz alleged that ...

ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United ...